Compare DSX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSX | MYGN |
|---|---|---|
| Founded | 1999 | 1991 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.1M | 372.1M |
| IPO Year | 2005 | 1996 |
| Metric | DSX | MYGN |
|---|---|---|
| Price | $2.53 | $4.13 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $4.11 |
| AVG Volume (30 Days) | 998.3K | ★ 1.6M |
| Earning Date | 11-19-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $8.68 | $5.47 |
| P/E Ratio | $16.02 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $1.60 | $2.74 |
| 52 Week High | $3.20 | $8.50 |
| Indicator | DSX | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 32.73 | 51.29 |
| Support Level | $2.27 | $2.89 |
| Resistance Level | $2.61 | $4.89 |
| Average True Range (ATR) | 0.10 | 0.26 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 9.57 | 19.41 |
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize, and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods, including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers, through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation; the services provided by the vessels are similar, and all operate under the same economic environment.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.